Aclaris Therapeutics Gains FDA Fast Track Designation for Modzatinib in Moderate to Severe Lichen Planus

With no approved therapies currently on the market for lichen planus, Aclaris Therapeutics has secured a regulatory pathway that compresses both development timelines and NDA review cycles. The FDA granted Fast Track Designation for modzatinib (ATI-2138) covering moderate to severe LP, including oral erosive LP, cutaneous LP, and lichen planopilaris.

For regulatory affairs leads, the designation's most operationally significant feature is rolling NDA review: completed sections can be submitted and assessed on an ongoing basis rather than held until the full application is assembled. That structural flexibility, when built into a submission timeline early, can meaningfully reduce the gap between final data lock and agency action. Fast Track-designated programs also become eligible for Priority Review if the relevant criteria are met at the time of NDA filing.

The designation additionally opens a channel for more frequent FDA interactions on development planning and clinical trial design. Aclaris intends to initiate a phased, multi-part Phase 2b trial of modzatinib in LP in the fourth quarter of 2026, making the quality of those pre-submission exchanges directly relevant to protocol design and endpoint selection over the near term.

Modzatinib is a JAK inhibitor candidate within Aclaris's immuno-inflammatory pipeline. Lichen planus is a chronic inflammatory condition affecting skin, mucous membranes, and hair follicles; the absence of any FDA-approved treatment places it squarely within the unmet medical need threshold the agency applies when evaluating Fast Track eligibility under 21 CFR Part 312.82.

Regulatory teams at clinical-stage organizations tracking this program should note that Fast Track status is not permanent: Aclaris's own risk disclosures flag the possibility that the designation could be withdrawn if the program no longer meets the qualifying criteria. Maintaining designation through Phase 2b will depend on the trial's ability to demonstrate continued alignment with the serious condition and unmet need standards.

The Phase 2b initiation timeline in Q4 2026 sets the first measurable checkpoint against which the practical value of this designation will be assessed.

Source: Aclaris Therapeutics, Inc. via GlobeNewswire, August 6, 2026.